City of Hope | Strategic Alliance Partners

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.

Successful manipulation of the immune system to achieve regression of cancer, long an unfulfilled goal of oncologic investigation, is an ever-increasing reality in multiple clinical settings.

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

Despite the favorable comments and interest in clinical trials, the objective fact is that a distressingly low percentage of patients with cancer, in the range of 2% to 4%, are enrolled in clinical investigative efforts.

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

Marwan G. Fakih, MD, discusses a comparative analysis of the tumor microenvironment in primary tumors vs metastatic tissue in patients with microsatellite stable metastatic colorectal cancer.

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.

Amandeep Salhotra, MD, provides insight on the data with Orca-Q shared during the 2022 ASH Annual Meeting.

Tanya Dorff, MD, discusses the exploration of triplet combination therapies in patients with metastatic hormone-sensitive prostate cancer.

because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

The combination of selinexor and ruxolitinib significantly reduced spleen volume and total symptom score while achieving hemoglobin stabilization in an open-label dose-escalation/dose-expansion, phase 1 study of patients with treatment-naïve myelofibrosis.

Tycel Phillips, MD, MPH, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma.

Chemotherapy prior to treatment with endocrine therapy could increase the risk of cancer-related cognitive impairment compared with endocrine therapy alone in women with breast cancer, irrespective of menopausal status.

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.

Murali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.

A core component of any type of therapeutic research is to enhance clinical benefit.